Promising combo tackles rare lymphoma in early trial
NCT ID NCT04433156
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of drugs called VR-CAP (bortezomib, rituximab, and chemotherapy) as a first treatment for people with marginal zone lymphoma, a rare blood cancer. 26 patients received up to 6 cycles of treatment. Researchers measured how long patients lived without the cancer getting worse and how many responded to treatment. The study is complete, but results are not yet widely reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VR-CAP (bortezomib, rituximab, cyclophosphamide, epirubicin, prednisone)
What this could lead to
If successful, this could offer a new first-line treatment option for marginal zone lymphoma, potentially improving disease control and survival.
What could go wrong
This is a small, early-phase trial with only 26 participants and no comparison group. Results may not apply to all patients, and side effects from chemotherapy and targeted drugs can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China